Clinical Trial Search

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations

Primary: Percentage of Participants With Change of Treated Lesions — 44; 44; 13 % of participants

Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Clearance Based on Photographic Scale — 2; 2; 4; 7 Participants

Primary: Change in Spots - Front of Face (Part 1) — 53.60; 58.47; 56.44 spots

Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants

Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 observations

Primary: Percentage of Participants With Histologically Confirmed Complete Response (CR) — 67; 18 percentage of participants — p=<0.001

Primary: Maximum Tolerated Dose — 8 J/cm2

Primary: Number of Participants That Performed Regular Self-Skin Examinations — 8; 16; 23; 25 participants — p=0.048

Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations

Primary: Mean Number of Facial Actinic Keratoses at Week 12 — 2.70 Lesions

Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants

Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12

Primary: Number of Participants With Histologically Confirmed Complete Response — 25; 11 Participants

Primary: Complete Clearance Rate — 16; 15; 10; 12 AK Fields

Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants

Primary: The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and…

Primary: Lab* Values of Lesional Area Using Dermoscopy and ImageJ — 68.850; 72.103; 73.147; 72.633 unitless

Primary: The Percentage of Eligible and Contacted Patients Who Were Randomised Into the Trial — 100 Participants

Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants

Primary: Correct Identification of Baseline Photographs vs. Photographs Taken 3 Months Post Last Treatment — 80 % of photos correctly identified

Primary: SciBase Sensitivity and Specificity — 96.6; 31.4 Percentage of total lesions — p=<0.0001

Primary: Proportion of Subjects With Lesion Clearance — 16 Participants

Primary: Physician's DPN Lesions Assessment — -0.75; -1.38; -0.92 score on a scale (PLA)